UBS upgrades this kidney treatment stock, says it could rally 30%
The firm upgraded shares to buy and raised its price target to a Street-high of $142, citing an upcoming inflection in treatment growth.
Source link
- Ukraine replaces Soviet hammer and sickle with trident on Kyiv monument
- India pushes ahead with data privacy bill despite pushback from critics | TechCrunch
